Dallas, December 13, 2021—What can you do with some 2022 insurance plans no longer covering Eliquis, Pradaxa, and Savaysa? What is the problem? We have become aware that CVS Caremark, the company that manages the prescription medications for many US health insurance plans, has decided to drop coverage for Eliquis, Pradaxa, and Savaysa from many …
Read More
Here's more good news about the upcoming antidote for Eliquis - see: Positive Results for Factor Xa Inhibitor Antidote: ANNEXA-A
Read More
Press Release: Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban) Friday, December 28, 2012 5:46 pm EST PRINCETON, N.J. & NEW YORK--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved ELIQUIS® (apixaban). Please see full Prescribing Information including BOXED WARNING and Medication Guide …
Read More
StopAfib.org interviews Dr. Daniel Singer of Harvard Medical School. Find more information on this topic, and Dr. Singer, at: http://www.stopafib.org/newsitem.cfm/NEWSID/397 Dr. Singer led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium. He provided an update on rivaroxaban …
Read More
A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …
Read More